What are you looking for? Write the name, title or any keyword related to what you are looking for and select which content category it belongs to. Search Fulltext search Activities Professionals Research groups News - Any - Year 2015 Referencia J Natl Cancer Inst. 2015 Sep 23;107(12). pii: djv258. doi: 10.1093/jnci/djv258. Print 2015 Dec. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1093/jnci/djv258 Revista JNCI-Journal of the National Cancer Institute Títol Complet A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. Factor d'impacte 12.58 Codi 6186 PMID https://pubmed.ncbi.nlm.nih.gov/26405092 Nom Autors Sclafani, Francesco, Kim, Tae Y, Cunningham, David, Kim, Tae W, Tabernero, Josep, Schmoll, Hans J, Roh, Jae K, Kim, Sun Y, Park, Young S, Guren, Tormod K et al. DOI número 10.1093/jnci/djv258 Year 2015 Referencia Ann Oncol. 2015 Sep;26(9):1936-41. doi: 10.1093/annonc/mdv285. Epub 2015 Jul 10. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1093/annonc/mdv285 Revista ANNALS OF ONCOLOGY Títol Complet Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. Factor d'impacte 7.04 Codi 6187 PMID https://pubmed.ncbi.nlm.nih.gov/26162609 Nom Autors Hahne, J C, Braconi, C, Tabernero, J, Glimelius, B, Cervantes, A, Begum, R, Gonzalez De Castro, D, Hulkki Wilson, S, Eltahir, Z, Wotherspoon, A et al. DOI número 10.1093/annonc/mdv285 Year 2015 Referencia Br J Cancer. 2015 Jun 9;112(12):1874-81. doi: 10.1038/bjc.2015.144. Epub 2015 May 19. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1038/bjc.2015.144 Revista BRITISH JOURNAL OF CANCER Títol Complet Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. Factor d'impacte 4.84 Codi 6188 PMID https://pubmed.ncbi.nlm.nih.gov/25989270 Nom Autors Macarulla, T, Cervantes, A, Tabernero, J, Rosello, S, Van Cutsem, E, Tejpar, S, Prenen, H, Martinelli, E, Troiani, T, Laffranchi, B et al. DOI número 10.1038/bjc.2015.144 Year 2015 Referencia J Natl Cancer Inst. 2015 Jan 31;107(2). pii: dju413. doi: 10.1093/jnci/dju413. Print 2015 Feb. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1093/jnci/dju413 Revista JNCI-Journal of the National Cancer Institute Títol Complet nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. Factor d'impacte 12.58 Codi 6189 PMID https://pubmed.ncbi.nlm.nih.gov/25638248 Nom Autors Goldstein, David, El-Maraghi, Robert Hassan, Hammel, Pascal, Heinemann, Volker, Kunzmann, Volker, Sastre, Javier, Scheithauer, Werner, Siena, Salvatore, Tabernero, Josep, Tortora, Giampaolo et al. DOI número 10.1093/jnci/dju413 Year 2015 Referencia Eur J Cancer. 2015 May;51(8):942-9. doi: 10.1016/j.ejca.2015.02.013. Epub 2015 Mar 25. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1016/j.ejca.2015.02.013 Revista EUROPEAN JOURNAL OF CANCER Títol Complet Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. Factor d'impacte 5.42 Codi 6190 PMID https://pubmed.ncbi.nlm.nih.gov/25818084 Nom Autors Van Cutsem, Eric, Macpherson, Iain R, Strumberg, Dirk, Kohne, Claus-Henning, Zalcberg, John, Wagner, Andrea, Luigi Garosi, Vittorio, Grunert, Julia, Tabernero, Josep, Ciardiello, Fortunato et al. DOI número 10.1016/j.ejca.2015.02.013 Year 2015 Referencia Eur J Cancer. 2015 Jul;51(10):1231-42. doi: 10.1016/j.ejca.2015.03.026. Epub 2015 May 5. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1016/j.ejca.2015.03.026 Revista EUROPEAN JOURNAL OF CANCER Títol Complet Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Factor d'impacte 5.42 Codi 6191 PMID https://pubmed.ncbi.nlm.nih.gov/25956209 Nom Autors Douillard, Jean-Yves, Siena, Salvatore, Peeters, Marc, Koukakis, Reija, Terwey, Jan-Henrik, Tabernero, Josep et al. DOI número 10.1016/j.ejca.2015.03.026 Year 2015 Referencia Oncologist. 2015 Feb;20(2):143-50. doi: 10.1634/theoncologist.2014-0394. Epub 2015 Jan 12. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1634/theoncologist.2014-0394 Revista ONCOLOGIST Títol Complet Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Factor d'impacte 4.87 Codi 6192 PMID https://pubmed.ncbi.nlm.nih.gov/25582141 Nom Autors Weekes, Colin, Tabernero, Josep, Chiorean, E Gabriela, Infante, Jeffrey R, Hingorani, Sunil R, Ganju, Vinod, Goldstein, David, Penenberg, Darryl N, Romano, Alfredo, Ferrara, Stefano et al. DOI número 10.1634/theoncologist.2014-0394 Year 2015 Referencia Cell Oncol (Dordr). 2015 Feb;38(1):3-16. doi: 10.1007/s13402-014-0203-7. Epub 2015 Jan 14. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1007/s13402-014-0203-7 Revista CELLULAR ONCOLOGY Títol Complet Intrinsic cancer subtypes--next steps into personalized medicine. Factor d'impacte 3.03 Codi 6193 PMID https://pubmed.ncbi.nlm.nih.gov/25586691 Nom Autors Santos, Cristina, Sanz-Pamplona, Rebeca, Nadal, Ernest, Grasselli, Julieta, Pernas, Sonia, Dienstmann, Rodrigo, Moreno, Victor, Tabernero, Josep, Salazar, Ramon et al. DOI número 10.1007/s13402-014-0203-7 Year 2015 Referencia J Clin Oncol. 2015 Jun 1;33(16):1787-96. doi: 10.1200/JCO.2014.60.0213. Epub 2015 Apr 27. Tipus publicació Review in national publication DOI http://dx.doi.org/10.1200/JCO.2014.60.0213 Revista JOURNAL OF CLINICAL ONCOLOGY Títol Complet Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. Factor d'impacte 18.43 Codi 6194 PMID https://pubmed.ncbi.nlm.nih.gov/25918287 Nom Autors Dienstmann, Rodrigo, Salazar, Ramon, Tabernero, Josep et al. DOI número 10.1200/JCO.2014.60.0213 Year 2015 Referencia Clin Cancer Res. 2015 Nov 1;21(21):4811-8. doi: 10.1158/1078-0432.CCR-14-3222. Epub 2015 Jul 13. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1158/1078-0432.CCR-14-3222 Revista CLINICAL CANCER RESEARCH Títol Complet SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial. Factor d'impacte 8.72 Codi 6195 PMID https://pubmed.ncbi.nlm.nih.gov/26169969 Nom Autors Menendez, Camino, Tabernero, Josep, Romano, Alfredo, Wei, Xinyu, Lopez-Rios, Fernando, Von Hoff, Daniel D, Lopez-Casas, Pedro P, Pierce, Daniel, Brachmann, Carrie B, Hidalgo, Manuel et al. DOI número 10.1158/1078-0432.CCR-14-3222 Year 2015 Referencia Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1016/S1470-2045(15)70127-0 Revista LANCET ONCOLOGY Títol Complet Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Factor d'impacte 24.69 Codi 6196 PMID https://pubmed.ncbi.nlm.nih.gov/25877855 Nom Autors Laplaige, Philippe, Tabernero, Josep, Yoshino, Takayuki, Cohn, Allen Lee, Obermannova, Radka, Bodoky, Gyorgy, Garcia-Carbonero, Rocio, Ciuleanu, Tudor-Eliade, Portnoy, David C, Van Cutsem, Eric et al. DOI número 10.1016/S1470-2045(15)70127-0 Year 2015 Referencia N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309. Tipus publicació Clinical guide DOI http://dx.doi.org/10.1056/NEJMoa1502309 Revista NEW ENGLAND JOURNAL OF MEDICINE Títol Complet Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. Factor d'impacte 55.87 Codi 6197 PMID https://pubmed.ncbi.nlm.nih.gov/26287849 Nom Autors Hyman, David M, Puzanov, Igor, Subbiah, Vivek, Faris, Jason E, Chau, Ian, Blay, Jean-Yves, Wolf, Jurgen, Raje, Noopur S, Diamond, Eli L, Hollebecque, Antoine et al. DOI número 10.1056/NEJMoa1502309 Year 2015 Referencia Cancer Discov. 2015 Jun;5(6):598-609. doi: 10.1158/2159-8290.CD-14-1432. Epub 2015 May 11. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1158/2159-8290.CD-14-1432 Revista Cancer Discovery Títol Complet Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Factor d'impacte 19.45 Codi 6198 PMID https://pubmed.ncbi.nlm.nih.gov/25962717 Nom Autors Dienstmann, Rodrigo, Patnaik, Amita, Garcia-Carbonero, Rocio, Cervantes, Andres, Benavent, Marta, Rosello, Susana, Tops, Bastiaan B J, van der Post, Rachel S, Argiles, Guillem, Skartved, Niels J O et al. DOI número 10.1158/2159-8290.CD-14-1432 Year 2015 Referencia Lancet Oncol. 2015 Aug;16(8):937-48. doi: 10.1016/S1470-2045(15)00138-2. Epub 2015 Jul 13. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1016/S1470-2045(15)00138-2 Revista LANCET ONCOLOGY Títol Complet Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Factor d'impacte 24.69 Codi 6199 PMID https://pubmed.ncbi.nlm.nih.gov/26184520 Nom Autors Bouche, Olivier, Mineur, Laurent, Barone, Carlo, Adenis, Antoine, Yoshino, Takayuki, Goldberg, Richard M, Sargent, Daniel J, Wagner, Andrea, Laurent, Dirk, Teufel, Michael et al. DOI número 10.1016/S1470-2045(15)00138-2 Year 2015 Referencia N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1056/NEJMoa1414325 Revista NEW ENGLAND JOURNAL OF MEDICINE Títol Complet Randomized trial of TAS-102 for refractory metastatic colorectal cancer. Factor d'impacte 55.87 Codi 6200 PMID https://pubmed.ncbi.nlm.nih.gov/25970050 Nom Autors Tabernero, Josep, Mayer, Robert J, Van Cutsem, Eric, Falcone, Alfredo, Yoshino, Takayuki, Garcia-Carbonero, Rocio, Mizunuma, Nobuyuki, Yamazaki, Kentaro, Shimada, Yasuhiro, Scheithauer, Werner et al. DOI número 10.1056/NEJMoa1414325 Year 2015 Referencia Cancer Discov. 2015 Nov;5(11):1164-77. doi: 10.1158/2159-8290.CD-15-0369. Epub 2015 Sep 26. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1158/2159-8290.CD-15-0369 Revista Cancer Discovery Títol Complet Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Factor d'impacte 19.45 Autors Elena Antima Martinez Saez Codi 6201 PMID https://pubmed.ncbi.nlm.nih.gov/26410082 Nom Autors Signoretti, Sabina, Cibulskis, Kristian, Ligon, Keith L, Tabernero, Josep, Seoane, Joan, Martinez-Saez, Elena, Curry, William T, Dunn, Ian F, Paek, Sun Ha, Park, Sung-Hye et al. DOI número 10.1158/2159-8290.CD-15-0369 Year 2015 Referencia Am Soc Clin Oncol Educ Book. 2015;35:e149-56. doi: 10.14694/EdBook_AM.2015.35.e149. Tipus publicació Letter or abstract DOI http://dx.doi.org/10.14694/EdBook_AM.2015.35.e149 Revista American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology Títol Complet Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer. Codi 6202 PMID https://pubmed.ncbi.nlm.nih.gov/25993166 Nom Autors Dienstmann, Rodrigo, Salazar, Ramon, Tabernero, Josep et al. DOI número 10.14694/EdBook_AM.2015.35.e149 Year 2015 Referencia Target Oncol. 2015 Mar;10(1):111-23. doi: 10.1007/s11523-014-0320-2. Epub 2014 Jun 15. Tipus publicació Clinical Trials DOI http://dx.doi.org/10.1007/s11523-014-0320-2 Revista Targeted Oncology Títol Complet Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Factor d'impacte 4.00 Codi 6203 PMID https://pubmed.ncbi.nlm.nih.gov/24928772 Nom Autors Tabernero, Josep, Brana, Irene, Calles, Antonio, LoRusso, Patricia M, Yee, Lorrin K, Puchalski, Thomas A, Seetharam, Shobha, Zhong, Bob, de Boer, Carla J, Calvo, Emiliano et al. DOI número 10.1007/s11523-014-0320-2 Year 2015 Referencia J Clin Oncol. 2015 Nov 10;33(32):3733-40. doi: 10.1200/JCO.2015.60.9107. Epub 2015 Aug 31. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1200/JCO.2015.60.9107 Revista JOURNAL OF CLINICAL ONCOLOGY Títol Complet Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. Factor d'impacte 18.43 Codi 6204 PMID https://pubmed.ncbi.nlm.nih.gov/26324362 Nom Autors Maroun, Jean, de Braud, Filippo, Price, Timothy, Van Cutsem, Eric, Hill, Mark, Hoersch, Silke, Rittweger, Karen, Haller, Daniel G, Tabernero, Josep, Schmoll, Hans-Joachim et al. DOI número 10.1200/JCO.2015.60.9107 Year 2015 Referencia Lancet Oncol. 2015 Jun;16(6):e262. doi: 10.1016/S1470-2045(15)70273-1. Epub 2015 May 27. Tipus publicació Review in international publication DOI http://dx.doi.org/10.1016/S1470-2045(15)70273-1 Revista LANCET ONCOLOGY Títol Complet Correction to Lancet Oncol 2015; 16: 499-508. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Factor d'impacte 24.69 Codi 6206 PMID https://pubmed.ncbi.nlm.nih.gov/26065608 Nom Autors Tabernero, J, Takayuki, Y, Cohn, A L et al. DOI número 10.1016/S1470-2045(15)70273-1 Pagination First page « Previous page ‹ … Page 575 Page 576 Current page 577 Page 578 Page 579 … Next page › Last page »
Year 2015 Referencia J Natl Cancer Inst. 2015 Sep 23;107(12). pii: djv258. doi: 10.1093/jnci/djv258. Print 2015 Dec. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1093/jnci/djv258 Revista JNCI-Journal of the National Cancer Institute Títol Complet A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. Factor d'impacte 12.58 Codi 6186 PMID https://pubmed.ncbi.nlm.nih.gov/26405092 Nom Autors Sclafani, Francesco, Kim, Tae Y, Cunningham, David, Kim, Tae W, Tabernero, Josep, Schmoll, Hans J, Roh, Jae K, Kim, Sun Y, Park, Young S, Guren, Tormod K et al. DOI número 10.1093/jnci/djv258
Year 2015 Referencia Ann Oncol. 2015 Sep;26(9):1936-41. doi: 10.1093/annonc/mdv285. Epub 2015 Jul 10. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1093/annonc/mdv285 Revista ANNALS OF ONCOLOGY Títol Complet Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. Factor d'impacte 7.04 Codi 6187 PMID https://pubmed.ncbi.nlm.nih.gov/26162609 Nom Autors Hahne, J C, Braconi, C, Tabernero, J, Glimelius, B, Cervantes, A, Begum, R, Gonzalez De Castro, D, Hulkki Wilson, S, Eltahir, Z, Wotherspoon, A et al. DOI número 10.1093/annonc/mdv285
Year 2015 Referencia Br J Cancer. 2015 Jun 9;112(12):1874-81. doi: 10.1038/bjc.2015.144. Epub 2015 May 19. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1038/bjc.2015.144 Revista BRITISH JOURNAL OF CANCER Títol Complet Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. Factor d'impacte 4.84 Codi 6188 PMID https://pubmed.ncbi.nlm.nih.gov/25989270 Nom Autors Macarulla, T, Cervantes, A, Tabernero, J, Rosello, S, Van Cutsem, E, Tejpar, S, Prenen, H, Martinelli, E, Troiani, T, Laffranchi, B et al. DOI número 10.1038/bjc.2015.144
Year 2015 Referencia J Natl Cancer Inst. 2015 Jan 31;107(2). pii: dju413. doi: 10.1093/jnci/dju413. Print 2015 Feb. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1093/jnci/dju413 Revista JNCI-Journal of the National Cancer Institute Títol Complet nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. Factor d'impacte 12.58 Codi 6189 PMID https://pubmed.ncbi.nlm.nih.gov/25638248 Nom Autors Goldstein, David, El-Maraghi, Robert Hassan, Hammel, Pascal, Heinemann, Volker, Kunzmann, Volker, Sastre, Javier, Scheithauer, Werner, Siena, Salvatore, Tabernero, Josep, Tortora, Giampaolo et al. DOI número 10.1093/jnci/dju413
Year 2015 Referencia Eur J Cancer. 2015 May;51(8):942-9. doi: 10.1016/j.ejca.2015.02.013. Epub 2015 Mar 25. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1016/j.ejca.2015.02.013 Revista EUROPEAN JOURNAL OF CANCER Títol Complet Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. Factor d'impacte 5.42 Codi 6190 PMID https://pubmed.ncbi.nlm.nih.gov/25818084 Nom Autors Van Cutsem, Eric, Macpherson, Iain R, Strumberg, Dirk, Kohne, Claus-Henning, Zalcberg, John, Wagner, Andrea, Luigi Garosi, Vittorio, Grunert, Julia, Tabernero, Josep, Ciardiello, Fortunato et al. DOI número 10.1016/j.ejca.2015.02.013
Year 2015 Referencia Eur J Cancer. 2015 Jul;51(10):1231-42. doi: 10.1016/j.ejca.2015.03.026. Epub 2015 May 5. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1016/j.ejca.2015.03.026 Revista EUROPEAN JOURNAL OF CANCER Títol Complet Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Factor d'impacte 5.42 Codi 6191 PMID https://pubmed.ncbi.nlm.nih.gov/25956209 Nom Autors Douillard, Jean-Yves, Siena, Salvatore, Peeters, Marc, Koukakis, Reija, Terwey, Jan-Henrik, Tabernero, Josep et al. DOI número 10.1016/j.ejca.2015.03.026
Year 2015 Referencia Oncologist. 2015 Feb;20(2):143-50. doi: 10.1634/theoncologist.2014-0394. Epub 2015 Jan 12. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1634/theoncologist.2014-0394 Revista ONCOLOGIST Títol Complet Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Factor d'impacte 4.87 Codi 6192 PMID https://pubmed.ncbi.nlm.nih.gov/25582141 Nom Autors Weekes, Colin, Tabernero, Josep, Chiorean, E Gabriela, Infante, Jeffrey R, Hingorani, Sunil R, Ganju, Vinod, Goldstein, David, Penenberg, Darryl N, Romano, Alfredo, Ferrara, Stefano et al. DOI número 10.1634/theoncologist.2014-0394
Year 2015 Referencia Cell Oncol (Dordr). 2015 Feb;38(1):3-16. doi: 10.1007/s13402-014-0203-7. Epub 2015 Jan 14. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1007/s13402-014-0203-7 Revista CELLULAR ONCOLOGY Títol Complet Intrinsic cancer subtypes--next steps into personalized medicine. Factor d'impacte 3.03 Codi 6193 PMID https://pubmed.ncbi.nlm.nih.gov/25586691 Nom Autors Santos, Cristina, Sanz-Pamplona, Rebeca, Nadal, Ernest, Grasselli, Julieta, Pernas, Sonia, Dienstmann, Rodrigo, Moreno, Victor, Tabernero, Josep, Salazar, Ramon et al. DOI número 10.1007/s13402-014-0203-7
Year 2015 Referencia J Clin Oncol. 2015 Jun 1;33(16):1787-96. doi: 10.1200/JCO.2014.60.0213. Epub 2015 Apr 27. Tipus publicació Review in national publication DOI http://dx.doi.org/10.1200/JCO.2014.60.0213 Revista JOURNAL OF CLINICAL ONCOLOGY Títol Complet Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. Factor d'impacte 18.43 Codi 6194 PMID https://pubmed.ncbi.nlm.nih.gov/25918287 Nom Autors Dienstmann, Rodrigo, Salazar, Ramon, Tabernero, Josep et al. DOI número 10.1200/JCO.2014.60.0213
Year 2015 Referencia Clin Cancer Res. 2015 Nov 1;21(21):4811-8. doi: 10.1158/1078-0432.CCR-14-3222. Epub 2015 Jul 13. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1158/1078-0432.CCR-14-3222 Revista CLINICAL CANCER RESEARCH Títol Complet SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial. Factor d'impacte 8.72 Codi 6195 PMID https://pubmed.ncbi.nlm.nih.gov/26169969 Nom Autors Menendez, Camino, Tabernero, Josep, Romano, Alfredo, Wei, Xinyu, Lopez-Rios, Fernando, Von Hoff, Daniel D, Lopez-Casas, Pedro P, Pierce, Daniel, Brachmann, Carrie B, Hidalgo, Manuel et al. DOI número 10.1158/1078-0432.CCR-14-3222
Year 2015 Referencia Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1016/S1470-2045(15)70127-0 Revista LANCET ONCOLOGY Títol Complet Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Factor d'impacte 24.69 Codi 6196 PMID https://pubmed.ncbi.nlm.nih.gov/25877855 Nom Autors Laplaige, Philippe, Tabernero, Josep, Yoshino, Takayuki, Cohn, Allen Lee, Obermannova, Radka, Bodoky, Gyorgy, Garcia-Carbonero, Rocio, Ciuleanu, Tudor-Eliade, Portnoy, David C, Van Cutsem, Eric et al. DOI número 10.1016/S1470-2045(15)70127-0
Year 2015 Referencia N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309. Tipus publicació Clinical guide DOI http://dx.doi.org/10.1056/NEJMoa1502309 Revista NEW ENGLAND JOURNAL OF MEDICINE Títol Complet Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. Factor d'impacte 55.87 Codi 6197 PMID https://pubmed.ncbi.nlm.nih.gov/26287849 Nom Autors Hyman, David M, Puzanov, Igor, Subbiah, Vivek, Faris, Jason E, Chau, Ian, Blay, Jean-Yves, Wolf, Jurgen, Raje, Noopur S, Diamond, Eli L, Hollebecque, Antoine et al. DOI número 10.1056/NEJMoa1502309
Year 2015 Referencia Cancer Discov. 2015 Jun;5(6):598-609. doi: 10.1158/2159-8290.CD-14-1432. Epub 2015 May 11. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1158/2159-8290.CD-14-1432 Revista Cancer Discovery Títol Complet Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Factor d'impacte 19.45 Codi 6198 PMID https://pubmed.ncbi.nlm.nih.gov/25962717 Nom Autors Dienstmann, Rodrigo, Patnaik, Amita, Garcia-Carbonero, Rocio, Cervantes, Andres, Benavent, Marta, Rosello, Susana, Tops, Bastiaan B J, van der Post, Rachel S, Argiles, Guillem, Skartved, Niels J O et al. DOI número 10.1158/2159-8290.CD-14-1432
Year 2015 Referencia Lancet Oncol. 2015 Aug;16(8):937-48. doi: 10.1016/S1470-2045(15)00138-2. Epub 2015 Jul 13. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1016/S1470-2045(15)00138-2 Revista LANCET ONCOLOGY Títol Complet Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Factor d'impacte 24.69 Codi 6199 PMID https://pubmed.ncbi.nlm.nih.gov/26184520 Nom Autors Bouche, Olivier, Mineur, Laurent, Barone, Carlo, Adenis, Antoine, Yoshino, Takayuki, Goldberg, Richard M, Sargent, Daniel J, Wagner, Andrea, Laurent, Dirk, Teufel, Michael et al. DOI número 10.1016/S1470-2045(15)00138-2
Year 2015 Referencia N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1056/NEJMoa1414325 Revista NEW ENGLAND JOURNAL OF MEDICINE Títol Complet Randomized trial of TAS-102 for refractory metastatic colorectal cancer. Factor d'impacte 55.87 Codi 6200 PMID https://pubmed.ncbi.nlm.nih.gov/25970050 Nom Autors Tabernero, Josep, Mayer, Robert J, Van Cutsem, Eric, Falcone, Alfredo, Yoshino, Takayuki, Garcia-Carbonero, Rocio, Mizunuma, Nobuyuki, Yamazaki, Kentaro, Shimada, Yasuhiro, Scheithauer, Werner et al. DOI número 10.1056/NEJMoa1414325
Year 2015 Referencia Cancer Discov. 2015 Nov;5(11):1164-77. doi: 10.1158/2159-8290.CD-15-0369. Epub 2015 Sep 26. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1158/2159-8290.CD-15-0369 Revista Cancer Discovery Títol Complet Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Factor d'impacte 19.45 Autors Elena Antima Martinez Saez Codi 6201 PMID https://pubmed.ncbi.nlm.nih.gov/26410082 Nom Autors Signoretti, Sabina, Cibulskis, Kristian, Ligon, Keith L, Tabernero, Josep, Seoane, Joan, Martinez-Saez, Elena, Curry, William T, Dunn, Ian F, Paek, Sun Ha, Park, Sung-Hye et al. DOI número 10.1158/2159-8290.CD-15-0369
Year 2015 Referencia Am Soc Clin Oncol Educ Book. 2015;35:e149-56. doi: 10.14694/EdBook_AM.2015.35.e149. Tipus publicació Letter or abstract DOI http://dx.doi.org/10.14694/EdBook_AM.2015.35.e149 Revista American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology Títol Complet Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer. Codi 6202 PMID https://pubmed.ncbi.nlm.nih.gov/25993166 Nom Autors Dienstmann, Rodrigo, Salazar, Ramon, Tabernero, Josep et al. DOI número 10.14694/EdBook_AM.2015.35.e149
Year 2015 Referencia Target Oncol. 2015 Mar;10(1):111-23. doi: 10.1007/s11523-014-0320-2. Epub 2014 Jun 15. Tipus publicació Clinical Trials DOI http://dx.doi.org/10.1007/s11523-014-0320-2 Revista Targeted Oncology Títol Complet Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Factor d'impacte 4.00 Codi 6203 PMID https://pubmed.ncbi.nlm.nih.gov/24928772 Nom Autors Tabernero, Josep, Brana, Irene, Calles, Antonio, LoRusso, Patricia M, Yee, Lorrin K, Puchalski, Thomas A, Seetharam, Shobha, Zhong, Bob, de Boer, Carla J, Calvo, Emiliano et al. DOI número 10.1007/s11523-014-0320-2
Year 2015 Referencia J Clin Oncol. 2015 Nov 10;33(32):3733-40. doi: 10.1200/JCO.2015.60.9107. Epub 2015 Aug 31. Tipus publicació Paper in international publication DOI http://dx.doi.org/10.1200/JCO.2015.60.9107 Revista JOURNAL OF CLINICAL ONCOLOGY Títol Complet Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. Factor d'impacte 18.43 Codi 6204 PMID https://pubmed.ncbi.nlm.nih.gov/26324362 Nom Autors Maroun, Jean, de Braud, Filippo, Price, Timothy, Van Cutsem, Eric, Hill, Mark, Hoersch, Silke, Rittweger, Karen, Haller, Daniel G, Tabernero, Josep, Schmoll, Hans-Joachim et al. DOI número 10.1200/JCO.2015.60.9107
Year 2015 Referencia Lancet Oncol. 2015 Jun;16(6):e262. doi: 10.1016/S1470-2045(15)70273-1. Epub 2015 May 27. Tipus publicació Review in international publication DOI http://dx.doi.org/10.1016/S1470-2045(15)70273-1 Revista LANCET ONCOLOGY Títol Complet Correction to Lancet Oncol 2015; 16: 499-508. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Factor d'impacte 24.69 Codi 6206 PMID https://pubmed.ncbi.nlm.nih.gov/26065608 Nom Autors Tabernero, J, Takayuki, Y, Cohn, A L et al. DOI número 10.1016/S1470-2045(15)70273-1
